Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > lots of misinformation going on here

<< Previous

Bullboard Posts

Next >>

Comment by Stormdog01on Jan 03, 2020 9:36am

106 Views

Post# 30514664

RE:lots of misinformation going on here

@Lifegoeson1973 Excellent post! I tend to agree with most of your points. As for the Vascepa % TG reduction numbers, I believe the 24% is after the FDA requested calculation adjustment while the 33% is pre-adjustment, just like ACST got 36% and 38% with 1g and 2g pre FDA adjustment. Pierre Lemieux confirmed it is the pre-adjustment numbers that will be used to benchmark against the 20% primary endpoiny target. To me this one is a slam dunk on the primary endpoint.

<< Previous

Bullboard Posts

Next >>

Infield Minerals to acquire Kings Canyon Gold Property